Listata mini, 60 mg 40 pcs

Listat mini is a lipase inhibitor.

Ingestion of orlistat inhibits gastric and pancreatic lipases. As a result, the breakdown of dietary fats is impaired and their absorption from the gastrointestinal tract is reduced.

When used systemically this effect leads to weight loss in obese patients.

Orlistat is practically not absorbed from the gastrointestinal tract and therefore has almost no resorptive effect.

Indications

Long-term therapy of obese patients with a BMI of at least 30 kg/m2 or overweight patients with a BMI of at least 28 kg/m2, incl. having risk factors associated with obesity, in combination with a moderately hypocaloric diet;

in combination with hypoglycemic drugs (metformin, sulfonylureas and/or insulin) and/or a moderately hypocaloric diet in patients with type 2 diabetes mellitus who are overweight or obese.

Pharmacological effect

Listata mini is a lipase inhibitor.

When taken orally, orlistat inhibits gastric and pancreatic lipases. As a result, the breakdown of dietary fats is disrupted and their absorption from the gastrointestinal tract is reduced.

When used systematically, this effect leads to a decrease in body weight in obese patients.

Orlistat is practically not absorbed from the gastrointestinal tract and therefore has virtually no resorptive effect.

Special instructions

Diet and exercise are important parts of a weight loss program. It is recommended to begin a dietary program and exercise before starting therapy with Listata Mini. The patient should receive a moderately hypocaloric diet containing no more than 30% of calories in the form of fat (for example, with a calorie content of 2000 kcal / meal should contain no more than 67 g of fat).

Daily fat intake should be distributed between three main meals.

A low-fat diet reduces the likelihood of developing gastrointestinal adverse events.

Patients taking antiepileptic drugs should consult a doctor before starting to use Listata Mini, because the frequency and severity of seizures may change. In these cases, taking orlistat and antiepileptic drugs at different times may be considered.

Patients with kidney disease should consult a doctor because… the development of hyperoxaluria and nephropathy is possible.

By reducing body weight while taking Listata Mini, it is possible to improve carbohydrate metabolism in patients with type 2 diabetes mellitus, and therefore it is necessary to consult with your doctor before starting to take orlistat and, if necessary, reduce the dose of hypoglycemic drugs

Weight loss may be accompanied by a decrease in blood pressure and cholesterol concentrations. Patients taking antihypertensive and lipid-lowering drugs should consult a doctor before starting orlistat and, if necessary, adjust the dose of these drugs.

If symptoms such as weakness, fatigue, fever, jaundice and dark urine appear, you should consult your doctor to rule out liver dysfunction.

Impact on the ability to drive vehicles and operate machinery.

Orlistat has no effect on
ability to drive vehicles and machinery.

Active ingredient

Orlistat

Composition

Active ingredient:

orlistat 60 mg;

Excipients:

sodium lauryl sulfate – 12 mg;

acacia gum – 210 mg;

ludiflash (mannitol – 84-92%, crospovidone – 4-6%, polyvinyl acetate – 3.5-6%, povidone – 0.25-0.6%) – 640 mg;

copovidone – 20 mg;

crospovidone – 50 mg;

magnesium stearate – 8 mg;

Film shell:

Opadry II blue (85F30720) (polyvinyl alcohol – 40%, titanium dioxide – 21.4%, macrogol 3350 – 20.2%, talc – 14.8%, quinoline yellow aluminum varnish – 0.1%, indigo carmine – 3.5%) – 34.8 mg; Opadry silver (63F97546) (polyvinyl alcohol – 47.03%, talc – 27%, macrogol 3350 – 13.27%, pearlescent pigment – 10%, polysorbate 80 – 2.7%) – 6 mg.

Contraindications

Hypersensitivity to orlistat or any other components of the drug;

chronic malabsorption syndrome;

pregnancy;

breastfeeding period;

children under 12 years old.

Side Effects

From the gastrointestinal tract: very often – oily discharge from the rectum, passage of gases with some discharge, imperative urge to defecate, steatorrhea; often – abdominal pain, fecal incontinence, loose stools, increased frequency of bowel movements.

Adverse effects reported post-marketing (frequency unknown)

From the gastrointestinal tract: minor bleeding from the rectum, diverticulitis.

From the liver and biliary tract: increased activity of liver transaminases and alkaline phosphatase, hepatitis, cholelithiasis.

From the skin and subcutaneous tissue: bullous rash.

From the immune system: hypersensitivity reactions (itching, rash, urticaria, angioedema, bronchospasm and anaphylaxis).

Other: decreased prothrombin concentration, increased INR in patients taking orlistat together with indirect anticoagulants.

Interaction

When taking orlistat and cyclosporine simultaneously, a decrease in the concentration of cyclosporine in the blood plasma is possible, and therefore it is necessary to monitor the content of cyclosporine in the blood plasma. The simultaneous use of Listata Mini and cyclosporine is contraindicated.

With simultaneous use of orlistat with amiodarone, a decrease in the concentration of amiodarone in the blood plasma is possible. The clinical significance of this effect is unclear. When taking orlistat and warfarin or other oral anticoagulants simultaneously, a decrease in prothrombin concentration and an increase in INR may be observed.

The simultaneous use of Listata Mini and warfarin or other oral anticoagulants is contraindicated.

Orlistat may reduce the absorption of fat-soluble vitamins A, D, E, K and beta-carotene. If multivitamins are indicated, they should be taken no earlier than 2 hours after taking orlistat or before bedtime.

Orlistat may reduce the absorption of antiepileptic drugs, which may lead to seizures.

Due to the lack of pharmacokinetic interaction studies, co-administration of orlistat and acarbose is not recommended.

In some cases, orlistat may indirectly reduce the bioavailability of oral contraceptives. In case of severe diarrhea, the use of an additional method of contraception is recommended.

When taken simultaneously with levothyroxine sodium, due to decreased absorption of inorganic iodine and/or levothyroxine sodium, hypothyroidism and/or decreased control of hypothyroidism may develop.

No drug interactions have been identified with
amitriptyline, atorvastatin, biguanides, digoxin, fibrates,
fluoxetine, losartan, phenytoin, phentermine, pravastatin, nifedipine,
sibutramine and ethanol.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years.

Manufacturer

Izvarino Pharma, Russia